Nutraceutical Ingredients Market worth $161.53 billion by 2031- Exclusive Report by MarketsandMarkets™

The global nutraceutical ingredients market is projected to rise from $108.33B in 2026 to $161.53B by 2031 (7.3% CAGR), supported by demand for preventive healthcare, digestive health, immunity, healthy aging, and sports nutrition. Growth is expected to be fastest in Asia Pacific (11.3% CAGR), with microbial-based ingredients projected to grow at 10.21% and human nutrition as the fastest-growing application segment (8.49% CAGR). The article also highlights investment and deal activity—including EVANIUM’s €2.2M seed funding (~$2.6M) to scale OPTISOLV and Glanbia’s $15.1M acquisition of Scicore Nutra—suggesting continued portfolio expansion and capacity buildout.

Analysis

This is a relative-value story, not a broad consumer demand trade. The market is likely to pay up for ingredient platforms that own formulation, fermentation, and local manufacturing capacity, because those assets convert category growth into pricing power; pure distributors and diversified food names with incidental exposure will not get the same multiple lift. That favors TATYY and GLAPF as cleaner public-market ways to express the theme, while ASBFY is a weaker vehicle because the equity story is diluted by unrelated operations.

The underappreciated second-order effect is margin dispersion: microbial and functional-protein growth is attractive only for firms with IP, regulatory know-how, and scale, so smaller regional players may actually face pressure as customers consolidate suppliers and demand clinical substantiation. In the next 1-3 months, the catalyst is guidance language on APAC mix, utilization, and pricing; over 6-18 months, the key question is whether capex and M&A translate into sustained EBITDA expansion or merely higher revenue with lower returns on capital. IFF looks like the most vulnerable name if the market decides its nutrition exposure is not pure enough to justify a rerating.

Contrarian view: consensus may be treating the market forecast as if it were earnings. The reported growth rate is real, but the beneficiaries will be narrow, and the biggest loser may be anyone selling commodity-like proteins or fibers without a differentiated claim stack. Falsifiers include a slowdown in supplement sell-through, a drop in APAC order growth, or evidence that price competition is forcing rebates despite healthy category demand.

Key Decisions for Investors

• Long TATYY / short IFF for 3-6 months: best risk/reward if the market starts rewarding pure-play functional fiber and APAC exposure over a more diversified nutrition-fragrance complex; thesis breaks if IFF shows unexpected nutrition margin expansion or TATYY misses utilization targets.
• Long GLAPF on pullbacks into earnings over the next 1-2 quarters: Glanbia has the clearest direct linkage to protein-led functional nutrition and M&A-supported portfolio depth; cut if Health & Nutrition growth falls below low-single digits or if margin gains are purely volume-driven.
• Avoid buying the broad consumer staples complex for this theme; if you want exposure, prefer a basket tilt toward ingredient enablers (TATYY, GLAPF) rather than XLP or generic food names that will not see multiple expansion from this growth pocket.
• Watchlist, not a trade yet: ASBFY only becomes interesting if its ingredients segment reports outsized margin expansion or new capacity monetization; otherwise the equity is too diluted to express the theme cleanly.
• Set an alert for APAC quarterly commentary and microbial-ingredient order growth: if growth stays above ~10% and pricing holds, the relative long in TATYY/GLAPF can extend; if not, the whole nutraceutical basket likely de-rates as the market realizes revenue growth is not the same as earnings power.